COMPPARE: A Path to Improve Future Health Outcomes for Men with Prostate Cancer

Thank you for your interest in the COMPPARE study. Patient enrollment is now closed.

COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study is funded by the Patient-Centered Outcomes Research Institute (PCORI) and led by Dr. Nancy Mendenhall at the University of Florida.

Are you a COMPPARE patient participant?

Participants stay current with us!Would you like to know about COMPPARE research updates, patient payment information, the VTOC portal, and providing survey input? Visit the COMPPARE Participant page.

About the study

COMPPARE enrolled 2,524 prostate cancer patients (ages 30-85) across the US who chose to be treated with proton therapy or photon therapy and answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years. Patient enrollment officially closed on October 31, 2022.

Use the links below to learn more about COMPPARE. 

A checkmark

Learn about study goals

A checkmark

Why is COMPPARE important?